What's in Illinois Retina Associates's pipeline?

Illinois Retina Associates has 2 drugs in our index: 1 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Illinois Retina Associates's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/illinois-retina-associates.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Illinois Retina Associates — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Illinois Retina Associates pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Ranibizumab plus Photodynamic therapy	Ranibizumab plus Photodynamic therapy	marketed	Anti-VEGF monoclonal antibody fragment combined with photodynamic therapy	VEGF-A (ranibizumab component)	Ophthalmology
proparacaine HCL 0.5%	proparacaine HCL 0.5%	phase 3

Therapeutic area mix

Ophthalmology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Illinois Retina Associates:

Cite this brief

Drug Landscape (2026). Illinois Retina Associates — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/illinois-retina-associates. Accessed 2026-05-16.